Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta HJ, McFadden G, Kaye FJ, Zajac-Kaye M. Kellish P, et al. Among authors: nawab a. J Clin Invest. 2019 Apr 29;129(6):2279-2292. doi: 10.1172/JCI121323. eCollection 2019 Apr 29. J Clin Invest. 2019. PMID: 31033480 Free PMC article.
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy.
Haritha NH, Nawab A, Vijayakurup V, Anto NP, Liju VB, Alex VV, Amrutha AN, Aiswarya SU, Swetha M, Vinod BS, Sundaram S, Guijarro MV, Herlevich T, Krishna A, Nestory NK, Bava SV, Sadasivan C, Zajac-Kaye M, Anto RJ. Haritha NH, et al. Among authors: nawab a. Front Oncol. 2021 Jul 15;11:656804. doi: 10.3389/fonc.2021.656804. eCollection 2021. Front Oncol. 2021. PMID: 34336653 Free PMC article.
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival.
Guijarro MV, Kellish PC, Dib PE, Paciaroni NG, Nawab A, Andring J, Kulemina L, Borrero NV, Modenutti C, Feely M, Nasri E, Seifert RP, Luo X, Bennett RL, Shabashvili D, Licht JD, McKenna R, Roitberg A, Huigens RW 3rd, Kaye FJ, Zajac-Kaye M. Guijarro MV, et al. Among authors: nawab a. JCI Insight. 2023 Apr 25;8(10):e158798. doi: 10.1172/jci.insight.158798. JCI Insight. 2023. PMID: 37097751 Free PMC article.
Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy.
Haritha NH, Nawab A, Vijayakurup V, Anto NP, Liju VB, Alex VV, Amrutha AN, Aiswarya SU, Swetha M, Vinod BS, Sundaram S, Guijarro MV, Herlevich T, Krishna A, Nestory NK, Bava SV, Sadasivan C, Zajac-Kaye M, Anto RJ. Haritha NH, et al. Among authors: nawab a. Front Oncol. 2023 Dec 15;13:1302413. doi: 10.3389/fonc.2023.1302413. eCollection 2023. Front Oncol. 2023. PMID: 38162481 Free PMC article.
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations.
Narayan S, Jaiswal AS, Sharma R, Nawab A, Duckworth LV, Law BK, Zajac-Kaye M, George TJ, Sharma J, Sharma AK, Hromas RA. Narayan S, et al. Among authors: nawab a. Oncotarget. 2017 Aug 1;8(34):57246-57264. doi: 10.18632/oncotarget.19778. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915668 Free PMC article.
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.
Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M. Chen M, et al. Among authors: nawab a. Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27. Mol Cancer Ther. 2012. PMID: 22203734 Free PMC article.
94 results